Study details
Enrolling now
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
NCT IDNCT06408194ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 1.6 years
Ages
1–25
Locations
1 site in CA
About this study
This trial is testing the safety and how well a new treatment, autologous CD22 CAR T cells, works when given after a commercial CAR T cell therapy called Tisagenlecleucel. The goal is to find out if this new treatment can be safely used in children and young adults with relapsed or refractory B-cell leukemia.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CD22CART infusion
- 2.Take Tisagenlecleucel
PhasePhase 1
DrugTisagenlecleucel
Routeinfusion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
tisagenlecleucel (CAR T-cell therapy targeting CD19 on leukemia cells)
Drug routes
infusion
Body systems
Oncology